Navigation Links
Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism
Date:11/11/2008

officer of Rigel. Results from both studies are expected to be available in late summer 2009.

TASKi2 will evaluate RA patients receiving 100 mg of R788 orally, twice a day or 150 mg once a day, compared with those receiving placebo in a multi- center, randomized, double blind, placebo controlled parallel dose study of RA patients who have failed to respond to methotrexate. TASKi2 will enroll 420 patients (all of whom have been identified) to receive study drug or placebo, along with their steady dose of methotrexate, over a 6 month treatment period.

TASKi3 will evaluate RA patients receiving 100 mg of R788 orally, twice a day, compared with those receiving placebo in a multi-center, randomized, double blind, placebo controlled, parallel dose study of R788 in patients who have failed at least one marketed biologic agent (i.e., anti-TNF injectibles commonly used to treat RA). Approximately 195 patients are expected to be enrolled in TASKi3. Each will receive R788 or placebo over a 3 month treatment period.

For more information about the TASKi studies and R788's mechanism of action in RA and other autoimmune disorders, please visit the company's website.

About Rigel (http://www.Rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

This press release contains "forward-looking" statements, inc
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
2. Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring
3. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
4. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
5. Patient Recruitment Begins in India for Phase 3 Diabetes Trial
6. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
7. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
8. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
9. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
10. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
11. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
(Date:12/24/2014)... 2014  Diplomat Pharmacy, Inc. (NYSE: DPLO ... to announce Jennifer Hagerman , Pharm.D., AE-C, senior ... office as the president of the Michigan Pharmacists Association ... take place Feb. 28, 2015, at the MPA Annual ... Renaissance Center in Detroit, Michigan . ...
(Date:12/24/2014)... NEW YORK and LONDON ... in global orthopedic industry are expected to grow at ... consumption in terms of value and volume. Hip, knee ... the developed world while in emerging economies they have ... failure rates are challenging the use of composites. Non-metallic ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... 15 Inverness Medical Innovations, Inc. (NYSE: IMA ... their health at home through the merger of rapid diagnostics and ... Alere Inc., after shareholders approved the name change at its Annual ... Company also announced that it expects its NYSE stock symbol to ...
... LAKE FOREST, Ill. , July 15 ... on the healthcare industry, announced today the closing of its third ... second captive subordinated debt fund of $200 million ("Capital ... million in March 2002 and its second equity ...
Cached Medicine Technology:RoundTable Healthcare Partners Closes Two Funds 2RoundTable Healthcare Partners Closes Two Funds 3
(Date:12/26/2014)... 2014 Plugin and template developers from ... Plugin for Final Cut Pro X. , “TransPack Volume 5 ... to pull off an industry professional look” Said Christina Austin, ... on TransPack Volume 5, a new level of professionalism will ... of over 50 Final Cut Pro X transitions featuring organic ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the Best ... 2014. The awards program, created in 2000, is one ... the country. The program is a public/private partnership between ... Economic Development, the Pennsylvania State Council of the Society ... Journal. , Charlie Wilson, Vice President of ...
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... 2014 The report “Nintedanib (Colorectal ... focuses on the current treatment landscape, unmet needs, ... cancer market. Stivarga is a drug which is ... cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an ... refractory CRC in the US, Europe, and Japan. ...
(Date:12/25/2014)... 2014 “Every three months the trends for ... sweetheart evening dress will be one of the hottest styles ... Yunx.co.uk says. Today, the company releases 26 A-line sweetheart evening ... 80% off. , “We are trying our best to ... our latest designs. Along with affordable prices, we provide discounted ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... been a considerable increase in the number of repeat cesarean ... 8-year study conducted between 1996 and 2003 survey has further ... unexplained reasons. ,According to National statistics, there has ... in women who have had a cesarean. Concomitantly, there has ...
... first step to retaining a good memory as we age is ... that they could control their memory are more likely to use ... ,The researchers analyzed the link between a sense of control ... and 83 years. The study participants were required to recall a ...
... pollution could be responsible for increase in cardiac and ... the recent issue of JAMA. , The ... disorders have been highlighted by numerous environment based studies. ... health is being perceived as a major public health ...
... of an association between aluminum salts contained in deodorants ... like cadmium and aluminum are believed to exert estrogen-like ... ,Under laboratory conditions, these salts have even ... cell lines, highlighting the carcinogenic potential of such compounds, ...
... increased over the last 10 years, a survey has found. ... ,A South Australian survey conducted between 1990 and 2003 ... from 7.3 percent in 1990 to 14.6 percent in 2003. ... people aged 55 and above. Overall the prevalence rate rose ...
... University of Illinois at Urbana-Champaign developed an innovative ... new drug and agricultural materials and delivery vehicles. ... engineering, chemistry and physics said that it was ... biofunctional capsules could be used in drug delivery, ...
Cached Medicine News:Health News:Want To Retain Your Memory? Believe That You Can Do So! 2Health News:Air Pollution Exposure Increases Risk Of Heart And Respiratory Disease 2Health News:Aluminum Salts In Underarm Deodorants Increase Risk Of Breast Cancer 2Health News:Medical Boon in the Form of a Biofriendly Capsule 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: